Efficacy
Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325)...
As with every medicine, when using REVOLADE, side effects can occur. In the case of serious side effects, it is possible that a dose adjustment is necessary. See also the Summary of Product Characteristics for a full overview of the side effects and...
TPO is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-R. Revolade interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar but...
Revolade dosing requirements must be individualised based on the patient's platelet counts. The lowest dose of eltrombopag to achieve and maintain a platelet count ≥50,000/µl should be used,...
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...